close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

24.21 -0.95 (-3.78%)
Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
COLL Q3 2026 deep dive: ADHD portfolio drives growth as pain business stabilizes
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) met Wall Street’s revenue expectations in Q3 2026, with sales up 3.3% year on year to $216.3 mi... 
Via StockStory
News headline image
1 profitable stock with solid fundamentals and 2 facing headwinds
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
Collegium (COLL) Q3 2026 Earnings Call Transcript ↗
Jornay PM growth outpaced a steep pain-segment drop this quarter. 
Via The Motley Fool
Topics Earnings
News headline image
Collegium Pharmaceutical Q3 Earnings Call Highlights ↗
Collegium Pharmaceutical (NASDAQ:COLL) reported record third-quarter 2026 revenue as growth in its attention-deficit/hyperactivity disorder portfolio helped offset declining sales of pain medicines.... 
Via MarketBeat
Topics Earnings
Collegium Pharmaceutical (NASDAQ:COLL) Posts Mixed Q3 as EPS Beats, Revenue Misses, and Guidance Holds ↗
Via Chartmill
Collegium Pharmaceutical (NASDAQ:COLL) Tumbles on Revenue Miss and Lowered Guidance ↗
Via Chartmill
News headline image
Collegium Pharmaceutical (NASDAQ:COLL) posts in line Q3 2026 sales and full year revenue guidance above estimates, stock soars
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) met Wall Street’s revenue expectations in Q3 2026, with revenue up 3.3% year on year to $216.3 ... 
Via StockStory
News headline image
Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Pharmaceutical (COLL) Q3 earnings: what to expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before the bell. Here’s what investors should... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 of Wall Street’s favorite stocks with promising prospects and 2 we turn down
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families 
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Q2 earnings highs and lows: Collegium Pharmaceutical (NASDAQ:COLL) vs the rest of the branded pharmaceuticals stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Collegium Pharmaceutical (NAS... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
Seven presentations include pediatric Phase 4 studies of AZSTARYS® (Serdexmethylphenidate/dexmethylphenidate) CII and real-world research of JORNAY PM® (Delayed-Release/Extended-Release... 
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
New resource hub builds on Collegium’s growing ADHD portfolio and commitment to supporting people and families beyond the clinical setting 
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
3 Healthcare Stocks That Concern Us
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
News headline image
3 Value Stocks That Fall Short
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
News headline image
1 Oversold Stock Ready to Bounce Back and 2 We Find Risky
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether... 
Via StockStory
News headline image
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
Topics Stocks
News headline image
Collegium to Participate in Upcoming Investor Conferences
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript ↗
Jornay PM revenue surged 41% as Collegium integrated Azstarys and expanded its sales force. 
Via The Motley Fool
Topics Earnings
News headline image
Collegium Announces $50 Million Accelerated Share Repurchase Program
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call
Collegium Pharmaceutical’s second quarter saw sales growth, but results missed Wall Street’s revenue expectations, leading to a negative market reaction. Man... 
Via StockStory
Topics Earnings
News headline image
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year ... 
Via StockStory
News headline image
Collegium Pharmaceutical Q2 Earnings Call Highlights ↗
Collegium Pharmaceutical (NASDAQ:COLL) reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower... 
Via MarketBeat
Topics Earnings
News headline image
Collegium Pharmaceutical (NASDAQ:COLL) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year ... 
Via StockStory
News headline image
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
News headline image
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting results this Thursday before market open. Here’s what to look for. Collegium ... 
Via StockStory
News headline image
Winners And Losers Of Q1: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
From Collegium Pharmaceutical, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.